Interaction of high-molecular-weight adiponectin concentration in blood serum with the risk of metabolic syndrome in women
https://doi.org/10.24884/1607-4181-2021-28-1-32-39
Abstract
Introduction. The development of metabolic syndrome (MS) in patients with abdominal obesity (AO) may be associated with a low level of the adiponectin (AN) - protective adipocytokine. AN circulates in the blood in various molecular forms.
The high molecular weight AN is assumed to have greater metabolic activity. It is currently not clear what level of high molecular weight adiponectin (HMWA) in women with AO is associated with MS and its components.
The objective was to study the role of high molecular weight adiponectin in the development of metabolic syndrome in women with abdominal obesity.
Methods and materials. 302 women with AO and 161 women without AO were examined. MS was diagnosed in 62.3 % of patients.
Results. The concentration of total adiponectin (TAN) and HMAN in the blood serum in women with MS was lower than in patients without MS (p<0.05). According to logistic regression analysis, the most significant factors influencing the risk of MS were low concentration of HMAN in the blood, age, and body mass index (p <0.05).
Conclusions. It was found that women with AO and HMAN concentration of less than 1.96 μg/ml in the blood had an increased risk of metabolic syndrome.
About the Authors
O. D. Belyaeva
Pavlov University; Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Belyaeva Olga D. - Dr. of Sci. (Med.), Associate Professor, Professor of the Department of Faculty Therapy with Courses of Endocrinology, Cardiology and Functional Diagnostics with Clinic, Pavlov University; Freelance Research Fellow of the Research Laboratory of Metabolic Syndrome of the Institute of Endocrinology, Almazov National Medical Research Centre.
6-8, L'va Tolstogo str., Saint Petersburg, 197022.
Competing Interests:
Authors declare no conflict of interest.
D. L. Brovin
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Brovin Dmitry L. - Cand. of Sci. (Med.), Assistant of the Department of Faculty Therapy with Courses of Endocrinology, Cardiology and Functional Diagnostics with Clinic, Pavlov University.
6-8, L'va Tolstogo str., Saint Petersburg, 197022.
Competing Interests:
Authors declare no conflict of interest.
O. A. Berkovich
Pavlov University; Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Berkovich Olga A. - Dr. of Sci. (Med.), Associate Professor, Professor of the Department of Faculty Therapy with Courses of Endocrinology, Cardiology and Functional Diagnostics with Clinic, Pavlov University; Freelance Research Fellow of the Research Laboratory of Metabolic Syndrome of the Institute of Endocrinology, Almazov National Medical Research Centre.
6-8, L'va Tolstogo str., Saint Petersburg, 197022.
Competing Interests:
Authors declare no conflict of interest.
T. L. Karonova
Pavlov University; Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Karonova Tatyana L. - Dr. of Sci. (Med.), Associate Professor, Professor of the Department of Faculty Therapy with Courses of Endocrinology, Cardiology and Functional Diagnostics with Clinic, Pavlov University; Head of the Research Laboratory of Clinical Endocrinology, Almazov National Medical Research Centre.
6-8, L'va Tolstogo str., Saint Petersburg, 197022.
Competing Interests:
Authors declare no conflict of interest.
N. A. Korelskaya
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Korelskaya Natalia A. - Cand. of Sci. (Med.), Associate Professor of the Department of Internal Diseases, Almazov National Medical Research Centre.
Saint Petersburg.
Competing Interests:
Authors declare no conflict of interest.
References
1. Gharipour M., Sadeghi M., Nezafati P., Dianatkhah M., Sarrafzadegan N. Cardiovascular Disease Risk Assessment: Triglyceride/High-Density Lipoprotein versus Metabolic Syndrome Criteria // J Res Health Sci. 2019; 19(2):e00442.
2. Cavallari I., Cannon C. P., Braunwald E. et al. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome // Eur J Prev Cardiol. 2018;25(8):830-838. Doi:10.1177/2047487318763897.
3. Zhernakova Yu. V., Zheleznova E. A., Chazova I. E. et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study - ESSE-RF // Terapevticheskii arkhiv. 2018;90(10):14-22. (In Russ.). Doi: 10.15829/1560-4071-2020-3815.
4. Sigit F. S., Tahapary D. L., Trompet S., Sartono E., Willems van Dijk K., Rosendaal F. R., de Mutsert R. The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: a cross-sectional analysis of two population-based studies // Diabetol Metab Syndr. 2020;(12):2. Doi: 10.1186/s13098-019-0503-1.
5. Saklayen M. G. The Global Epidemic of the Metabolic Syndrome // Curr Hypertens Rep. 201820(2):12. Doi: 10.1007/s11906-018-0812-z.
6. Kang D. R., Yadav D., Koh S. B., Kim J. Y., Ahn S. V. Impact of Serum Leptin to Adiponectin Ratio on Regression of Metabolic Syndrome in High-Risk Individuals: The ARIRANG Study // Yonsei Med J. 2017;58(2):339-346. Doi: 10.3349/ymj.2017.58.2.339.
7. Karuwanarint P., Phonrat B., Tungtrongchitr A., Suriyaprom K., Chuengsamarn S., Schweigert F. J., Tungtrongchitr R. Vitamin D-binding protein and its polymorphisms as a predictor for metabolic syndrome // Biomark Med. 2018; 12(5):465-473. Doi: 10.2217/bmm-2018-0029.
8. Tsertsvadze L. K., Avdeeva M. V., Scheglova L. V., Erina M. Y. Predictors of vetabolic syndrome in young men depending on the degree of ourification and reason of obesity // Modern Problems of Science and Education. 2019;5. (In Russ.).
9. Perez E. S., Medina M. A. G., Lomeli M. L., Gonzalez V T., Pérez J. Z. V, Lavalle Gonzalez F. J., Imrhan V, Juma S., Vijayagopal P., Boonme K., Prasad C. Association between serum uric acid and metabolic syndrome components in prepubertal obese children (Tanner Stage I) from Nuevo Leon, Mexico - a preliminary study // BMC Obes. 2017; (4):25. Doi: 10.1186/s40608-017-0160-6.
10. Kahn C. R., Wang G., Lee K. Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome // J Clin Invest. 2019;129(10):3990-4000. Doi: 10.1172/JCI12918.
11. Magaña Gomez J. A., Moreno-Mascareño D., Angulo Rojo C. E., de la Peña G. D. Association of Total and High Molecular Weight Adiponectin with Components of Metabolic Syndrome in Mexican Children // J Clin Res Pediatr Endocrinol. 2020;12(2):180-188. Doi: 10.4274/jcrpe.galenos.2019.2019.0113.
12. Ryu J., Loza C. A., Xu H. et al. Potential Roles of Adiponectin Isoforms in Human Obesity with Delayed Wound Healing // Cells. 2019;8(10):1134. Doi: 10.3390/cells8101134.
13. Brännmark C., Kay E. I., Örtegren Kugelberg U. et al. Adiponectin is secreted via caveolin 1-dependent mechanisms in white adipocytes // J Endocrinol. 2020;247(1):25-38. Doi: 10.1530/JOE-20-0078.
14. Mente A., Meyre D., Lanktree M. B., Heydarpour M.,. Davis A. D., Miller R. et al. Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population // PLoS ONE. 2013; 8(6):e66808. Doi: 10.1371/journal.pone.0066808.
15. Horakova D., Stepanek L., Nagelova R., Pastucha D., Azeem K., Kollarova H. Total and high-molecular-weight adiponectin levels and prediction of insulin resistance // Endokrynol Pol. 2018;69(4):375-380. Doi: 10.5603/EP.a2018.0035.
16. Prevalence of overweight and obesity among adults. Available at: http://www.who.int/gho/ncd/risk_factors/over-weight_obesity/obesity_adults/en (accessed: 12.02.2021).
17. Stanford F. C., Johnson E. D., Claridy M. D., Earle R. L., Kaplan L. M. The Role of Obesity Training in Medical School and Residency on Bariatric Surgery Knowledge in Primary Care Physicians // Int J Family Med. 2015:841249.
18. Parfenova N. S., Tanyanskiy D. A. Adiponectin: beneficial effects on metabolic and cardiovascular dysfunctions // Arterial'naya Gipertenziya = Arterial Hypertension. 2013; 19(1):84-96. (In Russ.) Doi: 10.18705/1607-419X-2013-19-1-84-96Y.
19. Premchandra Singh Y., Joshita L., Sukla Bablu Das et al. Plasma adiponectin is an independent predictor of metabolic syndrome // J Diabetes Metab. 2012;(3):8.
20. Liu Z., Liang S., Que S., Zhou L., Zheng S., Mardinoglu A. Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome //Front Physiol. 2018; (9):1238.
21. Acharya S. D., Evans R. W., Brooks M. M., Linkov F., Burke L. E. Total and high-molecular-weight adiponectin levels in relation to insulin resistance among overweight/ obese adults // Cent Asian J Glob Health. 2013;2(2):55. Doi: 10.5195/cajgh.2013.55.
22. Ford E. S., Giles W. H., Dietz W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey // JAMA. 2002; 287(3):356-359. Doi: 10.1001/jama.287.3.356.
23. Iwata M., Hara K., Kamura Y., Honoki H., Fujisaka S., Ishiki M. et al. Ratio of low molecular weight serum adiponectin to the total adiponectin value is associated with type 2 diabetes through its relation to increasing insulin resistance. PLoS ONE. 2018;13(3):e0192609. Doi: 10.1371/journal.pone.0192609.
24. Belyaeva O. D., Brovin D. I., Berezina A. V., Karonova T. L., Chubenko E. A., Baranova E. I., Berkovich O. A. Total and high-molecular weight adiponectin level in hypertensive women with abdominal obesity // Arterial'naya Gipertenziya = Arterial Hypertension. 2014;20(5):442-449. Doi: 10.18705/1607-419X-2014-20-5-442-449.
25. Falahi E., Khalkhali Rad A. H., Roosta S. What is the best biomarker for metabolic syndrome diagnosis? // Diabetes. Metab. Syndr. 2015;9(4):366-372.
26. Yuan G., Qian W., Pan R., Jia J., Jiang D., Yang Q., Wang S., Liu Y., Yu S., Hu H., Sun W., Ye J., Mao C., Zhuang R., Zhou L. Reduced circulating oxytocin and High-Molecular-Weight adiponectin are risk factors for metabolic syndrome // Endocr. J. 2016;63(7):655-662. Doi:10.1507/endocrj.EJ16-0078.
Review
For citations:
Belyaeva O.D., Brovin D.L., Berkovich O.A., Karonova T.L., Korelskaya N.A. Interaction of high-molecular-weight adiponectin concentration in blood serum with the risk of metabolic syndrome in women. The Scientific Notes of the Pavlov University. 2021;28(1):32-39. (In Russ.) https://doi.org/10.24884/1607-4181-2021-28-1-32-39
Views:
439
Email this article 